Compare Kaltura Inc (KLTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs TG Therapeutics Inc — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 41× Kaltura Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and TG Therapeutics Inc for 16 Days on average.
| KLTR | TGTX | |
|---|---|---|
Market Cap | $199.08M | $8.16B |
Volume | 175,927 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $1.89 | $59.06 |
52-Week Low | $1.08 | $26.94 |
Typical Hold Time | 21 Days | 16 Days |
Enterprise Value | $211.29M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.305, down 1.88% with bearish technical signals. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though still unprofitable. Recent positive developments include AI platform recognition and major streaming contracts, while valuation metrics remain elevated with P/S of 1.08 and EV/EBITDA of 271.59.
The outlook balances AI growth potential against persistent profitability challenges. Analyst consensus leans positive with 44% buy ratings, but high debt levels and negative cash flow present execution risks. The stock's direction hinges on AI monetization success and path to sustainable profitability.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
